Goldman Sachs maintained a sell rating on Dr Lal PathLabs with a target price of Rs 2200. The company reported a subdued volume growth and the trend continues.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
Goldman Sachs maintained a sell rating on Dr Lal PathLabs with a target price of Rs 2200. The company reported a subdued volume growth and the trend continues.
| Subscribe To Our Free Newsletter |
